SB-525 Continues to Show Encouraging Results for Hemophilia A in Phase 1/2 Trial
SB-525 is well-tolerated and leads to a dose-dependent increase in factor VIII in severe hemophilia A patients, a Phase 1/2 trial shows.
1 Comment
SB-525 Continues to Show Encouraging Results for Hemophilia A in Phase 1/2 Trial
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed